Screening for mutations in cancer-predisposition genes

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

With the publication of the results of the Human Genome Project, near-complete sequence information has become available theoretically to permit presymptomatic screening of all genes identified as relevant to cancer risk for the presence of heritable variation. This would include not only high-penetrance mutations but also polymorphic variants influencing cancer risk to a lesser degree. However, before genetic screening on such a large scale becomes a serious option, several issues remain to be addressed. The predominant issue in this respect is the clinical utility of genetic screening as standard practice. That is, does it reduce cancer morbidity and mortality through interventions that decrease cancer risk? Although genetic screening does exactly that in some isolated cases, at this stage it is fair to say that for many cancers the clinical validity and utility of such testing is debatable and more data are needed.1 While these issues are dealt with elsewhere in this book, the central question in this chapter is whether the state of current mutation analysis technology is actually capable of meeting the potential demand for large-scale genetic screening (for earlier reviews of the subject, see Mathew, 2 and Eng and Vijg3). Here, we will address the issue by first discussing the various criteria for an optimal genetic screening test in relation to its application. We will then present an overview of current and experimental methods for the detection of point mutations and small insertions, and deletions in clinical diagnostics. Finally, the future technological prospects in this field will be discussed.

Original languageEnglish (US)
Title of host publicationGenetic Predisposition to Cancer, Second Edition
PublisherCRC Press
Pages48-60
Number of pages13
ISBN (Electronic)9781444114287
ISBN (Print)9780340762547
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Neoplasm Genes
Genetic Testing
Screening
Genes
Mutation
Neoplasms
Human Genome Project
Penetrance
Point Mutation
Publications
Technology
Morbidity
Mortality
Testing

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Vijg, J., & Suh, Y. (2003). Screening for mutations in cancer-predisposition genes. In Genetic Predisposition to Cancer, Second Edition (pp. 48-60). CRC Press.

Screening for mutations in cancer-predisposition genes. / Vijg, Jan; Suh, Yousin.

Genetic Predisposition to Cancer, Second Edition. CRC Press, 2003. p. 48-60.

Research output: Chapter in Book/Report/Conference proceedingChapter

Vijg, J & Suh, Y 2003, Screening for mutations in cancer-predisposition genes. in Genetic Predisposition to Cancer, Second Edition. CRC Press, pp. 48-60.
Vijg J, Suh Y. Screening for mutations in cancer-predisposition genes. In Genetic Predisposition to Cancer, Second Edition. CRC Press. 2003. p. 48-60
Vijg, Jan ; Suh, Yousin. / Screening for mutations in cancer-predisposition genes. Genetic Predisposition to Cancer, Second Edition. CRC Press, 2003. pp. 48-60
@inbook{9c2d055096404d90a1a972b61755e7d6,
title = "Screening for mutations in cancer-predisposition genes",
abstract = "With the publication of the results of the Human Genome Project, near-complete sequence information has become available theoretically to permit presymptomatic screening of all genes identified as relevant to cancer risk for the presence of heritable variation. This would include not only high-penetrance mutations but also polymorphic variants influencing cancer risk to a lesser degree. However, before genetic screening on such a large scale becomes a serious option, several issues remain to be addressed. The predominant issue in this respect is the clinical utility of genetic screening as standard practice. That is, does it reduce cancer morbidity and mortality through interventions that decrease cancer risk? Although genetic screening does exactly that in some isolated cases, at this stage it is fair to say that for many cancers the clinical validity and utility of such testing is debatable and more data are needed.1 While these issues are dealt with elsewhere in this book, the central question in this chapter is whether the state of current mutation analysis technology is actually capable of meeting the potential demand for large-scale genetic screening (for earlier reviews of the subject, see Mathew, 2 and Eng and Vijg3). Here, we will address the issue by first discussing the various criteria for an optimal genetic screening test in relation to its application. We will then present an overview of current and experimental methods for the detection of point mutations and small insertions, and deletions in clinical diagnostics. Finally, the future technological prospects in this field will be discussed.",
author = "Jan Vijg and Yousin Suh",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780340762547",
pages = "48--60",
booktitle = "Genetic Predisposition to Cancer, Second Edition",
publisher = "CRC Press",

}

TY - CHAP

T1 - Screening for mutations in cancer-predisposition genes

AU - Vijg, Jan

AU - Suh, Yousin

PY - 2003/1/1

Y1 - 2003/1/1

N2 - With the publication of the results of the Human Genome Project, near-complete sequence information has become available theoretically to permit presymptomatic screening of all genes identified as relevant to cancer risk for the presence of heritable variation. This would include not only high-penetrance mutations but also polymorphic variants influencing cancer risk to a lesser degree. However, before genetic screening on such a large scale becomes a serious option, several issues remain to be addressed. The predominant issue in this respect is the clinical utility of genetic screening as standard practice. That is, does it reduce cancer morbidity and mortality through interventions that decrease cancer risk? Although genetic screening does exactly that in some isolated cases, at this stage it is fair to say that for many cancers the clinical validity and utility of such testing is debatable and more data are needed.1 While these issues are dealt with elsewhere in this book, the central question in this chapter is whether the state of current mutation analysis technology is actually capable of meeting the potential demand for large-scale genetic screening (for earlier reviews of the subject, see Mathew, 2 and Eng and Vijg3). Here, we will address the issue by first discussing the various criteria for an optimal genetic screening test in relation to its application. We will then present an overview of current and experimental methods for the detection of point mutations and small insertions, and deletions in clinical diagnostics. Finally, the future technological prospects in this field will be discussed.

AB - With the publication of the results of the Human Genome Project, near-complete sequence information has become available theoretically to permit presymptomatic screening of all genes identified as relevant to cancer risk for the presence of heritable variation. This would include not only high-penetrance mutations but also polymorphic variants influencing cancer risk to a lesser degree. However, before genetic screening on such a large scale becomes a serious option, several issues remain to be addressed. The predominant issue in this respect is the clinical utility of genetic screening as standard practice. That is, does it reduce cancer morbidity and mortality through interventions that decrease cancer risk? Although genetic screening does exactly that in some isolated cases, at this stage it is fair to say that for many cancers the clinical validity and utility of such testing is debatable and more data are needed.1 While these issues are dealt with elsewhere in this book, the central question in this chapter is whether the state of current mutation analysis technology is actually capable of meeting the potential demand for large-scale genetic screening (for earlier reviews of the subject, see Mathew, 2 and Eng and Vijg3). Here, we will address the issue by first discussing the various criteria for an optimal genetic screening test in relation to its application. We will then present an overview of current and experimental methods for the detection of point mutations and small insertions, and deletions in clinical diagnostics. Finally, the future technological prospects in this field will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=17044438386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044438386&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:17044438386

SN - 9780340762547

SP - 48

EP - 60

BT - Genetic Predisposition to Cancer, Second Edition

PB - CRC Press

ER -